Jacobs Levy Equity Management
PMVP icon

Jacobs Levy Equity Management’s PMV Pharmaceuticals PMVP Stock Holding History

Jacobs Levy Equity Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Sell
179,873
-344,477
-66% -$438K ﹤0.01% 907
2025
Q4 		$655K Buy
524,350
+455,682
+664% +$610K ﹤0.01% 761
2025
Q3 		$96.1K Buy
+68,668
New +$95K ﹤0.01% 941
2025
Q2 		– Sell
-129,914
Closed -$142K – 1140
2025
Q1 		$142K Sell
129,914
-409,979
-76% -$557K ﹤0.01% 1040
2024
Q4 		$815K Sell
539,893
-165,700
-23% -$262K ﹤0.01% 747
2024
Q3 		$1.05M Sell
705,593
-73,432
-9% -$113K ﹤0.01% 716
2024
Q2 		$1.26M Sell
779,025
-47,679
-6% -$86K 0.01% 686
2024
Q1 		$1.41M Buy
826,704
+397,062
+92% +$742K 0.01% 652
2023
Q4 		$1.33M Buy
+429,642
New +$1.14M 0.01% 675

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jacobs Levy Equity Management's PMVP Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its PMV Pharmaceuticals (PMVP) stake by 66% in Q1 2026, selling an estimated $438K and leaving 179,873 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #907.

Jacobs Levy Equity Management first reported a position in PMVP in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.41M in Q1 2024. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Jacobs Levy Equity Management held 179,873 shares of PMV Pharmaceuticals worth $223K as of Q1 2026.
  • Jacobs Levy Equity Management sold 344,477 PMV Pharmaceuticals shares in Q1 2026, an estimated $438K.
  • PMV Pharmaceuticals made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #907 holding.
  • Jacobs Levy Equity Management first reported a position in PMV Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • Jacobs Levy Equity Management's PMV Pharmaceuticals position peaked at $1.41M in Q1 2024.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.